This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ring, D. B. Articles by Nadji, M. Search for Related Content PubMed PubMed Citation Articles by Ring, D. B. Articles by Nadji, M.

Distribution and Physical Properties of BCA200, a M_r 200,000 Glycoprotein Selectively Associated with Human Breast Cancer

Cetus Corporation, Department of Immunology, [D. B. R., J. A. K., S. T. H-M., F. T., A. M. E., S. A. R.] and Department of Protein Chemistry [M. J. B.], Emeryville, California 94608; Division of Hematology/Oncology, Duke University Medical Center, Durham, North Carolina 27710 [A. E. F.]; and Department of Pathology, University of Miami School of Medicine, Miami, Florida 33101 [M. N.]

Of 122 mouse monoclonal antibodies selective for human breast cancer, 13 immunoprecipitated an acidic glycoprotein from SK-Br-3 and ZR-75-30 human breast cancer cells. The antigen (BCA200) migrates with an apparent molecular weight of 200,000 on reducing and 180,000 on nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis, suggesting a single polypeptide chain with a folded domain stabilized by a disulfide bond. Cross-blocking and sandwich immunoassays detected at least three distinct antigenic determinants on BCA200. Scatchard experiments measured 1,000,000 to 5,000,000 antigen copies per SK-Br-3 cell. The tissue distribution of BCA200 was studied using two monoclonals to different epitopes. Neither antibody stained any cells in human blood. When frozen sections of 20 normal human tissues were immunoperoxidase stained, the only positive structures were mucinous glands of colon, transitional epithelium of bladder, sweat glands of skin, and acinar epithelium of breast. Antibody 454C11 stained 16 of 21 breast tumor frozen sections and 9 of 12 breast cancer cell lines, while antibody 520C9 stained 5 of 20 breast tumors and 4 of 10 breast cancer lines. Cross-reaction was observed with lung, prostatic, pancreatic, endometrial, and ovarian cancer, but not with lymphoma, melanoma, colon, stomach, bladder, or esophageal cancer. When conjugated to ricin A chain, 10 of 13 antibodies produced immunotoxins selectively cytotoxic to SK-Br-3 breast cancer cells.

¹ To whom requests for reprints should be addressed.

² Present address: NeoRx Corporation, 410 W. Harrison St., Seattle, WA 98119.

Received 12/15/86. Revised 1/ 3/89. Accepted 2/15/89.

This article has been cited by other articles:

				B. Stockmeyer, T. Beyer, W. Neuhuber, R. Repp, J. R. Kalden, T. Valerius, and M. Herrmann Polymorphonuclear Granulocytes Induce Antibody-Dependent Apoptosis in Human Breast Cancer Cells J. Immunol., November 15, 2003; 171(10): 5124 - 5129. [Abstract] [Full Text] [PDF]

				A. E. Frankel New HER2-directed Therapies for Breast Cancer.: Commentary re: C. I. Spiridon et al., Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity. Clin. Cancer Res., 8: 1720-1730, 2002. Clin. Cancer Res., June 1, 2002; 8(6): 1699 - 1701. [Full Text] [PDF]

				C. I. Spiridon, M.-A. Ghetie, J. Uhr, R. Marches, J.-L. Li, G.-L. Shen, and E. S. Vitetta Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity of a Human Breast Cancer Cell Line in Vitro and in Vivo Clin. Cancer Res., June 1, 2002; 8(6): 1720 - 1730. [Abstract] [Full Text] [PDF]

				W. L. W. Hazenbos, I. A. F. M. Heijnen, D. Meyer, F. M. A. Hofhuis, C. Renardel de Lavalette, R. E. Schmidt, P. J. A. Capel, J. G. J. van de Winkel, J. E. Gessner, T. K. van den Berg, et al. Murine IgG1 Complexes Trigger Immune Effector Functions Predominantly via Fc{gamma}RIII (CD16) J. Immunol., September 15, 1998; 161(6): 3026 - 3032. [Abstract] [Full Text] [PDF]

				T. Valerius, B. Stockmeyer, A. B. van Spriel, R. F. Graziano, I. E. van den Herik-Oudijk, R. Repp, Y. M. Deo, J. Lund, J. R. Kalden, M. Gramatzki, et al. Fcalpha RI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy Blood, December 1, 1997; 90(11): 4485 - 4492. [Abstract] [Full Text] [PDF]